Table 1. Clinical characteristics and plasma FGF-21 levels of patients with and without CAD.
| CAD(−) | P value | CAD | 1-VD | 2-VD | 3-VD | P value | |
|---|---|---|---|---|---|---|---|
| (n = 193) | CAD(−) vs. CAD | (n = 224) | (n = 92) | (n = 65) | (n = 67) | Among 4 groups | |
| Age (years) | 66 ± 11 | < 0.01 | 70 ± 10 | 69 ± 10 | 69 ± 10 | 73 ± 7 | < 0.01 |
| Gender (male) | 120 (62%) | < 0.01 | 171 (76%) | 70 (76%) | 46 (71%) | 55 (82%) | 0.02 |
| BMI (kg/m2) | 23.6 ± 4.5 | 0.06 | 23.7 ± 3.3 | 23.9 ± 3.3 | 23.7 ± 3.2 | 23.3 ± 3.3 | 0.85 |
| Hypertension | 126 (65%) | < 0.01 | 175 (78%) | 71 (77%) | 49 (75%) | 55 (82%) | 0.03 |
| SBP (mmHg) | 131 ± 21 | 0.88 | 131 ± 23 | 129 ± 23 | 137 ± 21 | 128 ± 23 | 0.07 |
| Diabetes mellitus | 26 (13%) | < 0.01 | 77 (34%) | 27 (29%) | 24 (37%) | 26 (39%) | < 0.01 |
| Smoking | 49 (25%) | 0.20 | 68 (30%) | 32 (35%) | 17 (26%) | 19 (28%) | 0.50 |
| Hyperlipidemia | 74 (38%) | < 0.01 | 132 (59%) | 52 (57%) | 40 (62%) | 40 (60%) | < 0.01 |
| Statin | 46 (24%) | < 0.01 | 101 (45%) | 40 (43%) | 28 (43%) | 33 (49%) | < 0.01 |
| LDL-C (mg/dL) | 111 ± 29 | 0.18 | 115 ± 32 | 112 ± 33 | 118 ± 32 | 115 ± 30 | 0.33 |
| HDL-C (mg/dL) | 58 ± 15 | < 0.01 | 51 ± 13 | 53 ± 14 | 49 ± 11 | 49 ± 12 | < 0.01 |
| FGF-21 level (pg/mL) | 25.9 [0.0, 105.3] | 0.38 | 26.0 [0.0, 86.1] | 37.2 [0.0, 88.6] | 19.4 [0.0, 77.6] | 0.0 [0.0, 63.4] | 0.21 |
| FGF-21 < 15.6 pg/mL | 81 (42%) | 0.50 | 104 (46%) | 36 (39%) | 32 (49%) | 36 (54%) | 0.30 |
| PAD (ABI < 0.9) | 5 (3%) | < 0.01 | 33 (15%) | 9 (10%) | 6 (9%) | 18 (27%) | < 0.01 |
| Antiplatelet drugs | 62 (32%) | < 0.01 | 134 (60%) | 50 (54%) | 46 (71%) | 38 (57%) | < 0.01 |
Data represent the mean ± SD or the number (%) of patients, with the exception of FGF-21 level which is presented as the median value and interquartile range. BMI indicates body mass index; SBP, systolic blood pressure; LDL-C, low-density lipoprotein cholesterol; and HDL-C, high-density lipoprotein cholesterol.